Evaluation of mucoadhesive carrier adjuvant: Toward an oral anthrax vaccine
Source abstract
Abstract
The aim of present study was to evaluate the potential of mucoadhesive alginate-coated chitosan microparticles (A-CHMp) for oral vaccine against anthrax. The zeta potential of A-CHMp was -29.7 mV, and alginate coating could prevent the burst release of antigen in simulated gastric fluid. The results indicated that A-CHMp was mucoadhesive in nature and transported it to the peyer's patch upon oral delivery. The immunization studies indicated that A-CHMp resulted in the induction of potent systemic and mucosal immune responses, whereas alum-adjuvanted rPA could induce only systemic immune response. Thus, A-CHMp represents a promising acid carrier adjuvant for oral immunization against anthrax.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Viral gastroenteritis research and epidemiology · Bacillus and Francisella bacterial research · Probiotics and Fermented Foods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Abramova FA · Proc Natl Acad Sci USA · 1993 · 90 · 229110.1073/pnas.90.6.2291 ↗
2. Berthold I · Vaccine · 2005 · 23 · 199310.1016/j.vaccine.2004.10.014 ↗
3. Bonferoni MC · Pharm Dev Technol · 1999 · 4 · 4510.1080/10837459908984223 ↗
4. Borges O · Int J Pharm · 2005 · 299 · 15510.1016/j.ijpharm.2005.04.037 ↗
5. 10.4049/jimmunol.170.11.563610.4049/jimmunol.170.11.5636 ↗
6. 10.1016/S0264-410X(02)00191-310.1016/S0264-410X(02)00191-3 ↗
7. Eldridge JH · I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release · 1990 · 11 · 205
8. Elson CO · J Immunol Methods · 1984 · 67 · 10110.1016/0022-1759(84)90089-9 ↗
9. Fellows PF · Vaccine · 2001 · 19 · 324110.1016/S0264-410X(01)00021-4 ↗
10. Gonzalez-Rodriguez ML · Int J Pharm · 2002 · 232 · 22510.1016/S0378-5173(01)00915-2 ↗
11. Grinberg LM · I. Quantitative microscopic findings. Mod Pathol · 2001 · 14 · 482
12. He P · Int J Pharm · 1998 · 166 · 7510.1016/S0378-5173(98)00027-1 ↗
13. Ivins BE · Vaccine · 1998 · 16 · 114110.1016/S0264-410X(98)80112-6 ↗
14. Jaganathan KS · Int J Pharm · 2005 · 294 · 2310.1016/j.ijpharm.2004.12.026 ↗
15. Jain S · J Pharm Pharmacol · 2006 · 58 · 30310.1211/jpp.58.3.0003 ↗
16. 10.1016/j.imlet.2005.04.00210.1016/j.imlet.2005.04.002 ↗
17. Lopez CR · STP Pharma Sci · 2000 · 10 · 69
18. 10.2174/15665241079106541710.2174/156652410791065417 ↗
19. 10.1016/j.vaccine.2011.04.11210.1016/j.vaccine.2011.04.112 ↗
20. Medina E · FEMS Immunol Med Microbiol · 2000 · 4 · 30510.1111/j.1574-695X.2000.tb01444.x ↗
21. Mishra N · Expert Opin Ther Pat · 2010 · 20 · 66110.1517/13543771003730425 ↗
22. Mosmann T · J Immunol Methods · 1983 · 5 · 5510.1016/0022-1759(83)90303-4 ↗
23. 10.1208/s12248-009-9169-110.1208/s12248-009-9169-1 ↗
24. Reuveny S · Infect Immun · 2001 · 69 · 288810.1128/IAI.69.5.2888-2893.2001 ↗
25. Rossi S · Pharm Dev Technol · 1999 · 4 · 55
26. 10.1081/DDC-10010518210.1081/DDC-100105182 ↗
27. Singh Y · J Biol Chem · 1989 · 64 · 1109910.1016/S0021-9258(18)60433-8 ↗
28. Smith MW · Exp Phys · 1995 · 80 · 73510.1113/expphysiol.1995.sp003882 ↗
29. Welkos S · J Med Microbiol · 2002 · 51 · 82110.1099/0022-1317-51-10-821 ↗
30. 10.1099/00221287-147-6-167710.1099/00221287-147-6-1677 ↗
31. Williamson ED · J Appl Microbiol · 1999 · 87 · 31510.1046/j.1365-2672.1999.00901.x ↗
32. Xu Y · Int J Pharm · 2003 · 250 · 21510.1016/S0378-5173(02)00548-3 ↗